Personal profile
Biography
Stephen Opat is the director of Clinical Haematology at Monash Health, a dynamic academic research organization that integrates the best evidence–base into routine patient care. It provides haematology care to a population of approximately 1.3 million, making it one of the largest services in Australia. Key leadership areas in clinical care and research include: Lymphoid cancer, chronic myeloid disorders, thromboembolic disease, haemoglobinopathy and transfusion medicine. It is an active member of a number of research organisations including the Monash Health Translation Precinct (MHTP), the Centre for Cancer Research (CCR) at the Hudson Institute of Medical Research, and the Australasian Leukaemia and Lymphoma Group. His particular interests include the diagnosis and management of lymphoma and chronic lymphocytic leukaemia, cancer genomics, disorders of iron metabolism, Gaucher disease and novel therapies. He is the principal investigator in over 30 clinical trials mainly in lymphoid cancer and founder of the Australasian Lymphoma and Related Diseases Registry. He has a strong interest in medical education, particularly in developing countries, and has lectured widely throughout the Asia-Pacific. He is extremely active in the Haematology Society of Australia and New Zealand where he currently serves as President.
Research area keywords
- Lymphoma
- Genomics
- Chronic Lymphocytic Leukaemia
- Cancer Immunology
- Cancer Cell Biology
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
-
SDG 3 Good Health and Well-being
Collaborations and top research areas from the last five years
-
An ALLG phase II trial of epcoritamab consolidation in high genomic risk and MRD+ CLL patients after first-line venetoclax + obinutuzumab.
Opat, S. (Primary Chief Investigator (PCI))
21/04/26 → 20/04/31
Project: Research
-
A prospective randomized phase I/II trial of venetoclax treatment (26 cycles) with 6 cycles or 12 cycles of epcoritamab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma AETHER trial (ABT199 + Epcoritamab THErapy for Relapsed/refractory CLL/SLL)
Opat, S. (Primary Chief Investigator (PCI))
20/04/26 → 19/04/31
Project: Research
-
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared with Venetoclax Plus Acalabrutinib in Patients with Previously Untreated Chronic Lymphocytic Leukemia
Opat, S. (Primary Chief Investigator (PCI))
4/03/26 → 3/03/31
Project: Research
-
Epidemiological Modelling of Australian Patients with Lymphoma
Irving, A. (Primary Chief Investigator (PCI)), Petrie, D. (Supervisor), McQuilten, Z. (Supervisor), Hawkes, E. (Supervisor), Wood, E. (Supervisor), Opat, S. (Supervisor), Barraclough, A. (Supervisor) & Williams, J. (Supervisor)
1/01/26 → 31/12/29
Project: Research
File -
A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/ Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Opat, S. (Primary Chief Investigator (PCI))
13/08/25 → 12/08/30
Project: Research
-
Comprehensive humoral and cellular immune responses to COVID-19 vaccination in adults with cancer
Body, A., Lal, L., Srihari, S., MacIntyre, C. R., Buttery, J., Ahern, E. S., Opat, S., Leahy, M. F., Hamad, N., Milch, V., Turville, S., Smith, C., Lineburg, K., Naing, Z., Rawlinson, W. & Segelov, E., 6 Feb 2025, In: Vaccine. 46, 12 p., 126547.Research output: Contribution to journal › Article › Research › peer-review
Open Access14 Link opens in a new tab Citations (Scopus) -
Indolent lymphoma: addressing the needs of survivors
Fedele, P. L. & Opat, S., 2025, In: Leukemia and Lymphoma. 66, 6, p. 1021-1035 15 p.Research output: Contribution to journal › Review Article › Research › peer-review
Open Access2 Link opens in a new tab Citations (Scopus) -
Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia
Heyman, B. M., Opat, S. S., Wahlin, B. E., Dimopoulos, M. A. C., Castillo, J. J., Tedeschi, A., Tam, C. S., Buske, C., Owen, R. G., Leblond, V., Trotman, J., Barnes, G., Chan, W. Y., Schneider, J., Allewelt, H., Cohen, A. & Matous, J. V., 25 Feb 2025, In: Blood Advances. 9, 4, p. 722-728 7 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access7 Link opens in a new tab Citations (Scopus) -
Ratifying the efficacy and safety of intensive induction chemotherapy for acute myeloid leukaemia by the Australasian Leukaemia & Lymphoma Group consensus approach
Tedjaseputra, A., Tey, A., Nalpantidis, A., Grigoriadis, G., Fleming, S., Vilcassim, S., Fedele, P. L., Low, M. S. Y., Yeh, P., Gilbertson, M., Bennett, A., Gregory, G. P., Oh, D., Gairns, D., Kaplan, Z., Chunilal, S. D., Brown, S., Opat, S., Chua, C. C. & Shortt, J., May 2025, In: Internal Medicine Journal. 55, 5, p. 749-759 11 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access2 Link opens in a new tab Citations (Scopus) -
Too soon to reject immunoglobulin replacement in CLL
Opat, S. & Salvaris, R., 28 Oct 2025, In: Blood Advances. 9, 20, p. 5380-5381 2 p.Research output: Contribution to journal › Letter › Other › peer-review
Open Access1 Link opens in a new tab Citation (Scopus)